Full Text View
Tabular View
No Study Results Posted
Related Studies
Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy
This study has been completed.
Study NCT00355082   Information provided by GlaxoSmithKline
First Received: July 19, 2006   Last Updated: May 15, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Epilepsy, Partial
Additional conditions recognized in this trial
Epilepsies, Partial
Epilepsy
More general conditions related to this trial
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Interventions listed in this trial
lamotrigine, 250 mg/day
lamotrigine, 300 mg/day
Additional drug interventions recognized in this trial
Lamotrigine
More general drug interventions related to this trial
Anticonvulsants
Calcium Channel Blockers
Cardiovascular Agents
Central Nervous System Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
GlaxoSmithKline


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services